Fidelity Advisor Biotechnology Fund Profit Margin

The latest profit margin for FBTTX is 10.86% as of January 2024. That compares with 10.25% in the prior-year period — up 5.9% year over year. That is below the sector sector average of 13.16%. Investors often review this figure alongside Fidelity Advisor Biotechnology Fund's historical trend and sector peers before judging valuation or financial health.

Over the past year, FBTTX's profit margin moved from 10.25% to 10.86% — a 5.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Fidelity Advisor Biotechnology Fund's valuation or profitability profile.

Against its sector companies, FBTTX currently prints 10.86% for profit margin, while the sector average sits near 13.16%. That is roughly 17.5% below the sector mean. Large gaps often invite a closer look at Fidelity Advisor Biotechnology Fund's growth, margins, and balance sheet.

Profit Margin shows how effectively Fidelity Advisor Biotechnology Fund converts resources into returns. At 10.86%, FBTTX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 10.25% in the prior-year period — up 5.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting FBTTX's profit margin (10.86%), review year-over-year change from 10.25%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.